美國圣猶大兒童研究醫(yī)院（St. Jude Children’s Research Hospital）的研究者發(fā)現(xiàn),，感冒疫苗似乎能夠?qū)χ旅那萘鞲胁《綡5N1型有些許抵抗的效果。這項由美國國家過敏與感染疾病研究院（NIAID）與美國黎巴嫩敘利亞聯(lián)合慈善會（ALSAC）所資助的研究結(jié)果，發(fā)表于二月13日的PLoS Medicine期刊中,。
「一年一次的流行性感冒疫苗，的確具有能夠幫助人們對抗禽流感病毒H5N1型侵襲的潛力,；」圣猶大兒童研究醫(yī)院傳染疾病部門病毒學科的Richard J. Webby博士表示,。
A型流感病毒一般是為具有八個基因區(qū)段的RNA病毒，其外套膜上的神經(jīng)胺酸酶（neuraminidase）與血球凝集素（hemagglutinin）做為分類與命名的依據(jù),。H5N1型病毒顧名思義,，即為血球凝集素第5型與神經(jīng)胺酸酶第1型的病毒株。
「一般疫苗的制備,，都以較大的血球凝集素作為抗原,；」美國食品藥物管理局的Matthew Sandbulte博士說?！傅芯空咛岢鲆陨窠?jīng)胺酸酶作為免疫基準的疫苗,，似乎相當有意思?！顾⒅赋?，以神經(jīng)胺酸酶作為抗原的疫苗來對付難以估算狀況的禽流感是個相當不錯的主意,。
部分英文原文：
Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed Humans
Matthew R. Sandbulte1, Gretchen S. Jimenez2, Adrianus C. M. Boon1, Larry R. Smith2, John J. Treanor3, Richard J. Webby1*
1 Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, 2 Vical, San Diego, California, United States of America, 3 Infectious Diseases Unit, University of Rochester, Rochester, New York, United States of America
Background
A pandemic H5N1 influenza outbreak would be facilitated by an absence of immunity to the avian-derived virus in the human population. Although this condition is likely in regard to hemagglutinin-mediated immunity, the neuraminidase (NA) of H5N1 viruses (avN1) and of endemic human H1N1 viruses (huN1) are classified in the same serotype. We hypothesized that an immune response to huN1 could mediate cross-protection against H5N1 influenza virus infection.
Methods and Findings
Mice were immunized against the NA of a contemporary human H1N1 strain by DNA vaccination. They were challenged with recombinant A/Puerto Rico/8/34 (PR8) viruses bearing huN1 (PR8-huN1) or avN1 (PR8-avN1) or with H5N1 virus A/Vietnam/1203/04. Additional naïve mice were injected with sera from vaccinated mice prior to H5N1 challenge. Also, serum specimens from humans were analyzed for reactivity with avN1. Immunization elicited a serum IgG response to huN1 and robust protection against the homologous challenge virus. Immunized mice were partially protected from lethal challenge with H5N1 virus or recombinant PR8-avN1. Sera transferred from immunized mice to naïve animals conferred similar protection against H5N1 mortality. Analysis of human sera showed that antibodies able to inhibit the sialidase activity of avN1 exist in some individuals.
Conclusions
These data reveal that humoral immunity elicited by huN1 can partially protect against H5N1 infection in a mammalian host. Our results suggest that a portion of the human population could have some degree of resistance to H5N1 influenza, with the possibility that this could be induced or enhanced through immunization with seasonal influenza vaccines.
更多原文鏈接：
http://medicine.plosjournals.org/archive/1549-1676/4/2/pdf/10.1371_journal.pmed.0040059-S.pdf
